Roth MKM analyst Kumaraguru Raja downgraded Apexigen to Neutral from Buy with a $1.40 price target following the company’s announcement that is was evaluating strategic alternatives and restructuring, citing uncertainty in strategy and a lack of clarity on the future of the company following the news. However, the firm still believes that liposarcoma "offers an achievable path to market" for sotigalimab given the significant unmet need and "promising" Phase 2 data.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on APGN:
- Apexigen announces review of strategic alternatives, 55% workforce reduction
- Apexigen Announces Approximately $2.8 Million Private Placement Financing
- Apexigen announces $2.8M private placement financing
- Apexigen resumed with a Buy at Roth Capital
- Another Setback for Cancer as APGN Surges
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue